triazoles has been researched along with Multiple Myeloma in 82 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (1.22) | 18.2507 |
| 2000's | 3 (3.66) | 29.6817 |
| 2010's | 32 (39.02) | 24.3611 |
| 2020's | 46 (56.10) | 2.80 |
| Authors | Studies |
|---|---|
| Green, K; Hashmi, H | 1 |
| Biran, N; Breeze, J; Chari, A; Choquet, S; Cornell, RF; Costa, L; Daniele, P; Delforge, M; Dimopoulos, MA; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Gavriatopoulou, M; Hoffman, JE; Kaminetzky, D; Kauffman, M; Laurent, F; Levy, M; Li, L; Lionel, K; Meuleman, N; Mohty, M; Moreau, P; Nooka, A; Parker, T; Podar, K; Raab, M; Richardson, P; Richter, J; Schiller, G; Schreder, M; Shacham, S; Shah, J; Siegel, D; Sundar, J; Tremblay, G; Tuchman, S; Vij, R; Vlummens, P; Vogl, D; Weisel, K | 1 |
| Ferrante, SA; Gorsh, B; Hogea, C; Hughes, R; Kapetanakis, V; Popat, R; Prawitz, T; Sarri, G; Suvannasankha, A; Wang, F; Willson, J | 1 |
| Ando, K; Kawada, H; Kitamura, Y; Ogawa, Y; Ogiya, D; Suzuki, R | 1 |
| Ammu, S; Bahlis, NJ; Baljevic, M; Ben-Shahar, O; Bensinger, WI; Bentur, OS; Biran, N; Callander, NS; Chen, CI; DeCastro, A; Gasparetto, C; Kauffman, M; Kotb, R; LeBlanc, R; Lentzsch, S; Lipe, B; Madan, S; Rossi, AC; Schiller, GJ; Sebag, M; Shacham, S; Shah, J; Sutherland, HJ; Tuchman, SA; Van Domelen, D; Venner, CP; White, D; Zhang, C; Zhou, T | 1 |
| Chalopin, T; Nsiala, L | 1 |
| Arazy, M; Auner, HW; Benjamin, R; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Garg, MK; Gavriatopoulou, M; Grosicki, S; Hájek, R; Kauffman, MG; Leleu, X; Levy, Y; Mateos, MV; Moreau, P; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Sinha, DK; Venner, CP | 1 |
| Chari, A; Costa, LJ; Gasparetto, CJ; Jagannath, S; Lentzsch, S; Mikhael, J; Nooka, AK; Richardson, PG; Siegel, DS | 1 |
| Che, J; Dong, X; Guo, Y; Jin, X; Lu, Y; Qu, B; Shen, Z; Shi, Q; Tong, L; Wu, Y; Xu, Y; Yan, S; Yang, H; Zhuang, W | 1 |
| An, G; Cai, Z; Chang, C; Chen, L; Chen, W; Chen, X; Fang, B; Fu, C; Fu, W; Gao, S; Jing, H; Li, F; Liu, J; Liu, Z; Lynch, K; Qiu, L; Wang, A; Wei, Y; Weng, J; Xia, Z; Xiang, W; Yu, Y; Yu, Z | 1 |
| Chen, SL; Chen, XQ; Dai, YJ; Hu, F; Li, XP; Liang, Y; Lu, YX; Wang, DW | 1 |
| Ben-Shahar, O; Cass, M; Kashyap, T; Landesman, Y; McDonald, AB | 1 |
| Agte, S; Aleman, A; Bhalla, S; Chari, A; Cho, HJ; Ghodke-Puranik, Y; Jagannath, S; Jiang, J; Laganà, A; Landesman, Y; Leshchenko, V; Madduri, D; Melnekoff, DT; Parekh, S; Restrepo, P; Richard, S; Richter, J; Walker, CJ | 1 |
| Banerjee, A; Berdeja, JG; Deraedt, W; Diels, J; Jackson, CC; Jagannath, S; Krishnan, A; Martin, T; Nesheiwat, T; Schecter, JM; Usmani, SZ; Valluri, S; Van Sanden, S; Vogel, M; Weisel, K; Yalniz, F; Yeh, TM | 1 |
| Garate, GM; Ochoa, PA; Remaggi, G | 1 |
| Goldsmith, SR; Liu, L; Shiah, K | 1 |
| Bartley, BR; Doan, HQ; Landes, JR; Moore, SA; Rady, PL; Tyring, SK | 1 |
| Syed, YY | 1 |
| Chang, H; Chari, A; Choquet, S; Cole, C; Comenzo, RL; Cornell, RF; Costa, LJ; Crochiere, M; Delforge, M; Dimopoulos, M; Dingli, D; Doyen, C; Engelhardt, M; Facon, T; Frenzel, L; Gavriatopoulou, M; Hoffman, JE; Huff, CA; Illmer, T; Jagannath, S; Kaminetzky, D; Karlin, L; Kauffman, MG; Landesman, Y; Levy, M; Li, L; Lonial, S; Meuleman, N; Mohty, M; Moreau, P; Nooka, AK; Parekh, S; Parker, TL; Perrot, A; Picklesimer, C; Podar, K; Raab, MS; Richardson, PG; Richter, J; Saint-Martin, JR; Schiller, G; Schreder, M; Shacham, S; Shah, J; Stewart, AK; Tang, S; Tuchman, S; Vij, R; Vlummens, P; Vogl, DT; Weisel, KC; Yee, AJ | 1 |
| Stirrups, R | 1 |
| Romero, D | 1 |
| Jhaveri, KD; Wanchoo, R | 1 |
| Chari, A; Jagannath, S; Vogl, DT | 1 |
| Baz, R; Nishihori, T | 1 |
| Chari, A; Jagannath, S; Podar, K; Richardson, PG; Shah, J | 1 |
| Abou-Zeid, LA; Ashour, HF; El-Sayed, MA; Selim, KB | 1 |
| Chung, D; Diab, V; Drullinsky, P; Giralt, S; Hassoun, H; Hultcrantz, M; Korde, N; Lahoud, O; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Mailankody, S; Mastey, D; Salcedo, M; Schlossman, J; Scordo, M; Shah, G; Shah, U; Smith, E; Werner, K | 1 |
| Gill, J; Haslam, A; Prasad, V | 1 |
| Chakraborty, R; Efficace, F | 1 |
| Abonour, R; Bahlis, N; Baz, R; Berdeja, JG; Chai, Y; Chari, A; Chen, C; Choquet, S; Cornell, RF; Dimopoulos, MA; Dingli, D; Gasparetto, C; Gavriatopoulou, M; Hofmeister, CC; Huff, CA; Jagannath, S; Jakubowiak, A; Kauffman, MG; Lentzsch, S; Li, K; Li, L; Lonial, S; Mohty, M; Moreau, P; Nooka, AK; Parker, TL; Reece, D; Richter, J; Shacham, S; Shah, J; Siegel, D; Tuchman, S; Unger, TJ; Vogl, DT; Weisel, KC; White, D; Yee, AJ | 1 |
| Chari, A; DeCastro, A; Jagannath, S; Jakubowiak, A; Jasielec, J; Kauffman, M; Shacham, S; Shah, J; Unger, TJ; Vogl, DT | 1 |
| Chari, A; Costa, LJ; Faiman, B; Gleason, C; Jagannath, S; Lentzch, S; Mikhael, J; Nooka, AK; Noonan, KR; Richardson, PG; Siegel, D | 1 |
| Ahmann, GJ; Bergsagel, PL; Bonolo de Campos, C; Braggio, E; Bruins, LA; Darvish, SA; Dingli, D; Fonseca, R; Henderson, KJ; Kapoor, P; Kruse, JJ; Kumar, SK; Larsen, JT; Lopez Armenta, ID; Meurice, N; Petit, JL; Polito, AN; Reeder, CB; Stewart, AK; Stewart, WM; Tian, S; Wang, P; Wang, X; Zhu, YX | 1 |
| Jagannath, S; Richard, S; Richter, J | 1 |
| Avigdor, A; Geva, M; Magen, H; Nagler, A; Volchik, Y | 1 |
| Biran, N; Callander, N; Chari, A; Chhabra, S; Cornell, R; Costa, L; Fiala, MA; Gahvari, Z; Gandhi, U; Godby, K; Gupta, R; Hari, P; Jagannath, S; Jagosky, M; Kang, Y; Kansagra, A; Kauffman, M; Kodali, S; Kumar, SK; Lakshman, A; Liedtke, M; Lonial, S; Ma, X; Malek, E; Mansour, J; McGehee, EF; Neppalli, A; Paul, B; Richardson, P; Scott, EC; Shacham, S; Shah, J; Siegel, DS; Tang, S; Umyarova, E; Usmani, SZ; Varnado, W; Vij, R | 1 |
| Chari, A; Cho, HJ; DeCastro, A; Jagannath, S; Landesman, Y; Madduri, D; Mouhieddine, TH; Parekh, S; Richter, J; Shah, J | 1 |
| Bauer, AA; Cubitt, CL; Cui, Y; Dalton, WS; Dawson, JL; Gomez, JA; Kim, J; Nishihori, T; Sullivan, DM; Turner, JG | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, AZ; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Doronin, V; Facon, T; Garg, M; Gavriatopoulou, M; Grosicki, S; Hájek, R; Jagannath, S; Jeha, J; Kauffman, MG; Kriachok, I; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Forsberg, P; Mark, TM; Sherbenou, D; Stalker, M | 1 |
| Ayers, D; Cope, S; Davies, FE; Delforge, M; Dhanasiri, S; Hege, K; Jansen, JP; Mojebi, A; Rodriguez-Otero, P; Weisel, K | 1 |
| Delimpasi, S; Dimopoulos, MA; Grosicki, S; Kauffman, MG; Moreau, P; Richardson, PG | 1 |
| Bahlis, NJ; Biran, N; Chari, A; Gasparetto, C; Jagannath, S; Lonial, S; Mo, CC; Nooka, AK; Richardson, P; Siegel, D | 1 |
| Degnan, AP; Everlof, G; Fang, H; Fanslau, C; Gavai, AV; Haarhoff, Z; Hill, MD; Huang, C; Kramer, M; Lee, F; Marsilio, F; Menard, K; Monereau, L; Morrison, J; Ranasinghe, A; Sheriff, S; Shields, EE; Tokarski, J; Tye, CK; Westhouse, R; Yan, C; Zhang, L; Zvyaga, T | 1 |
| Anderson, LD; Arazy, M; Auner, HW; Badros, A; Bahlis, NJ; Benjamin, R; Cavo, M; Chai, Y; Chang, H; Chari, A; Delimpasi, S; Dimopoulos, MA; Dolai, TK; Facon, T; Garg, M; Grosicki, S; Hajek, R; Jagannath, S; Kauffman, MG; Kriachok, I; Landesman, Y; Leleu, X; Levy, M; Mateos, MV; Moreau, P; Pour, L; Pylypenko, H; Quach, H; Richard, S; Richardson, PG; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Spicka, I; Stevens, DA; Usenko, G; Venner, CP | 1 |
| Bar, N; Di, M; Giri, S; Huntington, SF; Parker, T; Patel, KK | 1 |
| Anderson, LD; Auner, HW; Bahlis, NJ; Beaumont, JL; Benjamin, R; Cavo, M; Chai, Y; Delimpasi, S; Dimopoulos, MA; Facon, T; Garg, MK; Grosicki, S; Hájek, R; Hudgens, S; Illmer, T; Jagannath, S; Kauffman, M; Kriachok, I; Leleu, X; Leong, H; Levy, M; Ma, X; Pour, L; Quach, H; Richardson, P; Sanchez, L; Shacham, S; Shah, J; Simonova, M; Sinha, DK; Špička, I; Stevens, DA; Tang, S; Usenko, G; Venner, C; Yu, H | 1 |
| Abid, H; Abid, MB; Wu, JF | 1 |
| Dolph, M; Leong, H; Tremblay, G | 1 |
| Castellon, C; Chaquette, R; Meleveedu, KS; Onkarappa Mangala, Y; Perez Rodriguez, A | 1 |
| Bhalla, S; Chari, A; Cho, H; Dhadwal, A; Florendo, E; Jagannath, S; Jiang, G; Lagana, A; Madduri, D; Mancia, IS; Parekh, S; Richter, J; Thomas, J | 1 |
| Abonour, R; Ahmann, G; Baz, R; Bhutani, D; Chari, A; Choe-Juliak, C; Cole, C; Cornell, RF; Costa, LJ; Dingli, D; Fonseca, R; Hoffman, JE; Huff, CA; Jagannath, S; Jakubowiak, A; Kaminetzky, D; Kauffman, M; Lopez, I; Nooka, A; Parker, TL; Picklesimer, CD; Richter, J; Saint-Martin, JR; Schiller, G; Shacham, S; Siegel, D; Stewart, AK; Van Wier, S; Vij, R; Vogl, DT; Yee, AJ; Zonder, J | 1 |
| Burki, TK | 1 |
| Baloglu, E; Chari, A; Cornell, RF; Gandhi, UH; Senapedis, W; Unger, TJ; Vogl, D | 1 |
| Aljama, MA; Dingli, D; Sidiqi, MH | 1 |
| Gourd, E | 1 |
| Anderson, KC; Avet-Loiseau, H; Bradner, JE; Fulciniti, M; Lawlor, MA; Lin, CY; Lopez, MA; Munshi, NC; Ott, CJ; Samur, MK; Singh, I; Szalat, RE; Young, RA | 1 |
| Dai, Y; Jiang, W; Jiang, Y; Liu, X; Xu, Y; Zhang, C | 1 |
| Abruzzese, MP; Bilotta, MT; Cippitelli, M; Fionda, C; Molfetta, R; Paolini, R; Petrucci, MT; Ricciardi, MR; Santoni, A; Soriani, A; Zingoni, A | 1 |
| Chari, A; Cole, CE; Hycner, T; Jakubowiak, AJ; Jasielec, JK; Karrison, T; McIver, A; Mikhael, J; Nam, J; Rosebeck, S; Rosenbaum, CA; Severson, E; Stephens, LA; Tinari, K; Turowski, A; Zimmerman, TM; Zonder, JA | 1 |
| Bradner, JE; Hoke, HA; Lau, A; Lee, TI; Lin, CY; Lovén, J; Orlando, DA; Vakoc, CR; Young, RA | 1 |
| Sebestyén, Z; Szabó, B; Szepesi, K | 1 |
| Bhatia, R; Donohue, C; Forman, SJ; Krishnan, A; Meng, Z; Pullarkat, V; Synold, TW; Tomassetti, S; Yamamoto, VN | 1 |
| Chevassut, TJ; Ghurye, RR; Stewart, HJ | 1 |
| Jin, HY; Kandela, I; Owen, K | 1 |
| Alonge, MM; Dytfeld, D; Jakubowiak, AJ; Jasielec, J; Kandarpa, M; Kauffman, M; Kraftson, SJ; Maxwell, SP; Mayampurath, A; McCauley, D; Rosebeck, S; Shacham, S; Volchenboum, SL | 1 |
| Assanelli, A; Barbanti, MC; Bernardi, M; Carrabba, M; Ciceri, F; Corti, C; Forcina, A; Giglio, F; Greco, R; Lupo Stranghellini, MT; Marktel, S; Messina, C; Morelli, M; Oltolini, C; Peccatori, J; Piemontese, S; Scarpellini, P; Vago, L | 1 |
| Aiba, K; Arakawa, Y; Kitagawa, M; Suzuki, K; Yamada, H; Yamamoto, K | 1 |
| Baz, R; Dai, Y; Dalton, WS; Dawson, JL; Grant, S; Kauffman, M; Meads, M; Shacham, S; Shain, KH; Sullivan, DM; Turner, JG | 1 |
| Arihara, Y; Hayasaka, N; Iyama, S; Kamihara, Y; Kato, J; Kawano, Y; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Sato, T; Sato, Y; Takada, K; Usami, M | 1 |
| Hawkes, N | 1 |
| Bauer, AA; Dai, Y; Dawson, JL; Gomez, J; Grant, S; Kashyap, T; Landesman, Y; Meads, M; Shain, KH; Sullivan, DM; Turner, JG | 1 |
| Desai, A; Gong, T; Lu, P; Wang, M; Zeng, D; Zhang, K | 1 |
| Aird, F; Kandela, I; Mantis, C | 1 |
| Abe, M; Fujii, S; Harada, T; Jinno, T; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Ozaki, S; Takeuchi, K; Yata, K | 1 |
| Anderson, KC; Bergsagel, PL; Bradner, JE; Chesi, M; Delmore, JE; Ghobrial, IM; Gilpatrick, T; Hahn, WC; Heffernan, TP; Issa, GC; Jacobs, HM; Kastritis, E; Kung, AL; Lemieux, ME; McKeown, MR; Mitsiades, CS; Paranal, RM; Qi, J; Rahl, PB; Richardson, PG; Schinzel, AC; Shi, J; Vakoc, CR; Young, RA | 1 |
| Hashimoto, N; Hattori, Y; Kato, J; Koda, Y; Mori, T; Okamoto, S; Sadahira, K; Shimizu, T; Tsukada, Y; Yamane, A; Yokoyama, K | 1 |
| Howden, BP; Mijch, AM; Schwarer, AP; Slavin, MA | 1 |
| Dinser, R; Grgic, A; Kim, YJ; Pfreundschuh, M; Schubert, J | 1 |
| Kalnicky, C; Klein, J; Mullane, K; Rodriguez, T; Stiff, P; Toor, AA | 1 |
| Audouin, AF; Breton, P; Germaud, P; Harousseau, JL; Milpied, N; Morin, O | 1 |
13 review(s) available for triazoles and Multiple Myeloma
| Article | Year |
|---|---|
The 'comeback' of Selinexor: From toxic to tolerable.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2022 |
Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Lymphoma, Non-Hodgkin; Multiple Myeloma; Triazoles | 2022 |
The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Cell Line, Tumor; Humans; Hydrazines; Karyopherins; Male; Multiple Myeloma; Triazoles | 2023 |
Selinexor: First Global Approval.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Triazoles | 2019 |
Selinexor for the treatment of multiple myeloma.
Topics: Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Clinical Trials as Topic; Dexamethasone; Drug Evaluation, Preclinical; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Prognosis; Receptors, Cytoplasmic and Nuclear; Triazoles | 2020 |
Consensus Recommendations for the Clinical Management of Patients With Multiple Myeloma Treated With Selinexor.
Topics: Consensus; Humans; Hydrazines; Multiple Myeloma; Practice Guidelines as Topic; Triazoles | 2020 |
Selinexor: a first-in-class SINE compound for treatment of relapsed refractory multiple myeloma.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Survival Rate; Triazoles | 2020 |
Selinexor for the treatment of patients with previously treated multiple myeloma.
Topics: Humans; Hydrazines; Karyopherins; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Triazoles | 2021 |
Risk for infections with selinexor in patients with relapsed/refractory multiple myeloma: a systematic review of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Humans; Hydrazines; Infections; Multiple Myeloma; Recurrence; Triazoles | 2021 |
Clinical Implications of Targeting XPO1-mediated Nuclear Export in Multiple Myeloma.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Drug Resistance, Neoplasm; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Treatment Outcome; Triazoles | 2018 |
Therapy for relapsed multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Decision Making; Gene Expression Profiling; Humans; Hydrazines; Immunotherapy; In Situ Hybridization, Fluorescence; Multiple Myeloma; Neoplasm Recurrence, Local; Stem Cell Transplantation; Sulfonamides; Symptom Assessment; Transplantation, Autologous; Triazoles; Watchful Waiting | 2018 |
[Pharmaceutical applications of sulfobuthylether-beta-cyclodextrin].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Antiemetics; Antifungal Agents; Antipsychotic Agents; Aripiprazole; beta-Cyclodextrins; Chemistry, Pharmaceutical; Dosage Forms; Drug Stability; Humans; Hungary; Multiple Myeloma; Oligopeptides; Piperazines; Pyrimidines; Quinolones; Quinuclidines; Solubility; Thiazoles; Triazoles; Voriconazole | 2013 |
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Boron Compounds; Congresses as Topic; Glycine; Humans; Hydrazines; Molecular Targeted Therapy; Multiple Myeloma; Proteasome Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Thiadiazoles; Treatment Outcome; Triazoles | 2017 |
13 trial(s) available for triazoles and Multiple Myeloma
| Article | Year |
|---|---|
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prognosis; Quality of Life; Survival Rate; Triazoles | 2021 |
Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Administration Schedule; Female; Humans; Hydrazines; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Oligopeptides; Survival Analysis; Translocation, Genetic; Treatment Outcome; Triazoles | 2022 |
Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrazines; Kidney Diseases; Male; Middle Aged; Multiple Myeloma; Survival Rate; Triazoles | 2022 |
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Multiple Myeloma; Proteasome Inhibitors; Triazoles | 2022 |
Matching-Adjusted Indirect Treatment Comparison to Assess the Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 Versus Belantamab Mafodotin in DREAMM-2, Selinexor-Dexamethasone in STORM Part 2, and Melphalan Flufenamide-Dexamethasone in HOR
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Melphalan; Multiple Myeloma; Triazoles | 2022 |
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Drug Administration Schedule; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Humans; Hydrazines; Intention to Treat Analysis; Karyopherins; Male; Middle Aged; Multiple Myeloma; Receptors, Cytoplasmic and Nuclear; Survival Analysis; Thrombocytopenia; Triazoles; Young Adult | 2019 |
Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Dexamethasone; Female; Glycine; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2020 |
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Dexamethasone; Disease-Free Survival; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Survival Rate; Triazoles | 2021 |
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cytogenetic Analysis; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Treatment Outcome; Triazoles; Young Adult | 2021 |
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Pain; Peripheral Nervous System Diseases; Triazoles | 2021 |
Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma.
Topics: Active Transport, Cell Nucleus; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Dose-Response Relationship, Drug; Exportin 1 Protein; Female; Humans; Hydrazines; Karyopherins; Male; Middle Aged; Multiple Myeloma; Progression-Free Survival; Receptors, Cytoplasmic and Nuclear; Triazoles | 2018 |
Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cytogenetic Analysis; Dexamethasone; Drug Resistance, Neoplasm; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Oligopeptides; Prognosis; Recurrence; Retreatment; Treatment Outcome; Triazoles | 2019 |
Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopsy; Cell Line, Tumor; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Exportin 1 Protein; Heterografts; Humans; Hydrazines; Karyopherins; Mice; Multiple Myeloma; Polyethylene Glycols; Receptors, Cytoplasmic and Nuclear; Survival Rate; Topoisomerase II Inhibitors; Triazoles; Tumor Burden | 2016 |
56 other study(ies) available for triazoles and Multiple Myeloma
| Article | Year |
|---|---|
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Standard of Care; Triazoles | 2021 |
Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Hydrazines; Multiple Myeloma; Triazoles; Tumor Cells, Cultured | 2022 |
[New European approval: Selinexor for triple class refractory multiple myeloma].
Topics: Administration, Oral; ADP-ribosyl Cyclase 1; Antibodies, Monoclonal, Humanized; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Europe; Humans; Hydrazines; Immunomodulating Agents; Membrane Glycoproteins; Multiple Myeloma; Proteasome Inhibitors; Recurrence; Triazoles | 2022 |
Guidance for Use and dosing of Selinexor in Multiple Myeloma in 2021: Consensus From International Myeloma Foundation Expert Roundtable.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Consensus; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2022 |
Design, synthesis and biological evaluation of sulfonamides inhibitors of XPO1 displaying activity against multiple myeloma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Hydrazines; Karyopherins; Multiple Myeloma; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Triazoles | 2022 |
Drug resistance biomarker ABCC4 of selinexor and immune feature in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Drug Resistance, Neoplasm; Hepatitis A Virus Cellular Receptor 2; Humans; Hydrazines; Karyopherins; Multidrug Resistance-Associated Proteins; Multiple Myeloma; Neoplasm Recurrence, Local; Receptors, Cytoplasmic and Nuclear; Triazoles | 2022 |
A Case Report of a 58-Year-Old Woman with a Diagnosis of High-Risk Myeloma Refractory to Multiple Line of Therapy and Treated with Selinexor, Bortezomib, and Dexamethasone Prior to Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
A Three-Gene Signature Predicts Response to Selinexor in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
Selinexor in Patients from Argentina with Multiple Myeloma Treated with Multiple Prior Therapies: A Case Series.
Topics: Antineoplastic Combined Chemotherapy Protocols; Argentina; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2022 |
Selinexor-dexamethasone for refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Dexamethasone; Humans; Hydrazines; Multicenter Studies as Topic; Multiple Myeloma; Retreatment; Triazoles | 2019 |
Responses to selinexor in multiple myeloma.
Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2019 |
Selinexor for Refractory Multiple Myeloma.
Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2019 |
Selinexor for Refractory Multiple Myeloma. Reply.
Topics: Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2019 |
Selective inhibitors of nuclear export (SINEs) in myeloma: breakthrough or bust?
Topics: Active Transport, Cell Nucleus; Antineoplastic Combined Chemotherapy Protocols; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2020 |
1,2,3-Triazole-Chalcone hybrids: Synthesis, in vitro cytotoxic activity and mechanistic investigation of apoptosis induction in multiple myeloma RPMI-8226.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Proliferation; Chalcones; Humans; Molecular Structure; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Triazoles; Tumor Cells, Cultured | 2020 |
Oncology Drug Advisory Committee Recommendations and the US Food and Drug Administration's Actions.
Topics: Advisory Committees; Drug Approval; Humans; Hydrazines; Multiple Myeloma; Triazoles; United States; United States Food and Drug Administration | 2020 |
Importance of quality of life in early phase clinical trials: A case study of selinexor in multiple myeloma.
Topics: Humans; Hydrazines; Multiple Myeloma; Quality of Life; Survival Analysis; Triazoles | 2020 |
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
Topics: Aged; Antineoplastic Agents; Appetite; Clinical Trials as Topic; Diarrhea; Fatigue; Female; Humans; Hydrazines; Hyponatremia; Male; Middle Aged; Multiple Myeloma; Nausea; Thrombocytopenia; Triazoles | 2020 |
Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy.
Topics: Adult; Aged; Cell- and Tissue-Based Therapy; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; Triazoles | 2020 |
"Direct to Drug" screening as a precision medicine tool in multiple myeloma.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Hydrazines; Multiple Myeloma; Precision Medicine; Sulfonamides; Triazoles; Tumor Cells, Cultured | 2020 |
Selinexor, Bortezomib, and Dexamethasone for Heavily Pretreated Multiple Myeloma: A Case Series.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Hydrazines; Middle Aged; Multiple Myeloma; Triazoles | 2020 |
Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
Melphalan and Exportin 1 Inhibitors Exert Synergistic Antitumor Effects in Preclinical Models of Human Multiple Myeloma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA Damage; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Fanconi Anemia Complementation Group D2 Protein; Humans; Hydrazines; Karyopherins; Melphalan; Mice, Inbred NOD; Multiple Myeloma; Nestin; Receptors, Cytoplasmic and Nuclear; Triazoles; Ubiquitination; Xenograft Model Antitumor Assays | 2020 |
Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Administration Schedule; Female; Frailty; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hydrazines; Kaplan-Meier Estimate; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Peripheral Nervous System Diseases; Progression-Free Survival; Randomized Controlled Trials as Topic; Retrospective Studies; Severity of Illness Index; Triazoles | 2021 |
Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Female; Humans; Hydrazines; Male; Multiple Myeloma; Triazoles | 2021 |
Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Male; Multiple Myeloma; Neoplasm Recurrence, Local; Oligopeptides; Transplantation, Homologous; Treatment Outcome; Triazoles | 2021 |
Matching adjusted indirect comparisons of efficacy outcomes for idecabtagene vicleucel (ide-cel, bb2121) versus selinexor + dexamethasone and belantamab mafodotin in relapsed and refractory multiple myeloma.
Topics: Antibodies, Monoclonal, Humanized; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles; United States | 2021 |
Multiple myeloma triplet therapies: baseline characteristics and control groups - Authors' reply.
Topics: Bortezomib; Boston; Control Groups; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Triazoles | 2021 |
Development of BET inhibitors as potential treatments for cancer: A search for structural diversity.
Topics: Animals; Antineoplastic Agents; Carbolines; Dose-Response Relationship, Drug; Drug Development; Humans; Mice; Molecular Structure; Multiple Myeloma; Proteins; Structure-Activity Relationship; Triazoles | 2021 |
Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Triazoles | 2021 |
Cost Effectiveness of Triplet Selinexor-Bortezomib-Dexamethasone (XVd) in Previously Treated Multiple Myeloma (MM) Based on Results from the Phase III BOSTON Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Boston; Cost-Benefit Analysis; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Neoplasm Recurrence, Local; Triazoles | 2021 |
First case report of tumor lysis syndrome and acute renal failure after selinexor use in multiple myeloma.
Topics: Acute Kidney Injury; Humans; Hydrazines; Multiple Myeloma; Triazoles; Tumor Lysis Syndrome | 2021 |
Optimal Supportive Care With Selinexor Improves Outcomes in Patients With Relapsed/Refractory Multiple Myeloma.
Topics: Humans; Hydrazines; Multiple Myeloma; Treatment Outcome; Triazoles | 2021 |
Selinexor and dexamethasone in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Dexamethasone; Humans; Hydrazines; Multiple Myeloma; Treatment Outcome; Triazoles | 2018 |
Promising new treatment for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase I as Topic; Humans; Hydrazines; Multiple Myeloma; Randomized Controlled Trials as Topic; Treatment Outcome; Triazoles | 2018 |
Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.
Topics: Animals; Azepines; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; E2F1 Transcription Factor; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Humans; Mice, SCID; Multiple Myeloma; Promoter Regions, Genetic; Protein Binding; Protein Domains; Protein Multimerization; Transcription Factor DP1; Transcriptome; Triazoles | 2018 |
AK-968 efficiently inhibits proliferation and induces cell apoptosis in human multiple myeloma cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Humans; Membrane Potential, Mitochondrial; Multiple Myeloma; Small Molecule Libraries; Triazoles | 2019 |
The homeobox transcription factor MEIS2 is a regulator of cancer cell survival and IMiDs activity in Multiple Myeloma: modulation by Bromodomain and Extra-Terminal (BET) protein inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Azepines; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Genes, Homeobox; Homeodomain Proteins; Humans; Immunomodulation; Multiple Myeloma; Protein Domains; Transcription Factors; Triazoles; Ubiquitin-Protein Ligases | 2019 |
Selective inhibition of tumor oncogenes by disruption of super-enhancers.
Topics: Antineoplastic Agents; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Chromatin; Enhancer Elements, Genetic; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Mediator Complex; Multiple Myeloma; Neoplasms; Nuclear Proteins; Transcription Elongation, Genetic; Transcription Factors; Transcription, Genetic; Triazoles | 2013 |
Iron chelators induce autophagic cell death in multiple myeloma cells.
Topics: Autophagy; Benzoates; Cell Line, Tumor; Cell Proliferation; Deferasirox; Deferoxamine; Drug Evaluation, Preclinical; Humans; Iron Chelating Agents; Multiple Myeloma; Primary Cell Culture; Reactive Oxygen Species; Triazoles | 2014 |
Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Azepines; Cell Survival; Enzyme-Linked Immunosorbent Assay; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Lipopolysaccharides; Male; Multiple Myeloma; Protein Structure, Tertiary; Real-Time Polymerase Chain Reaction; Triazoles | 2015 |
Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Topics: Animals; Antineoplastic Agents; Azepines; Disease Models, Animal; Down-Regulation; Gene Expression Regulation; Mice; Multiple Myeloma; Proto-Oncogene Proteins c-myc; Survival Analysis; Treatment Outcome; Triazoles | 2015 |
Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Caspase 10; Caspase 8; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Enzyme Activation; Humans; Hydrazines; Intracellular Space; Mice; Multiple Myeloma; Oligopeptides; Proteasome Inhibitors; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients.
Topics: Adolescent; Adult; Aged; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Remission Induction; Risk; Sirolimus; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Triazoles; Young Adult | 2016 |
Antimyeloma activity of bromodomain inhibitors on the human myeloma cell line U266 by downregulation of MYCL.
Topics: Antineoplastic Agents; Azepines; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Targeted Therapy; Multiple Myeloma; N-Myc Proto-Oncogene Protein; Protein Domains; Proto-Oncogene Proteins c-myc; Triazoles | 2016 |
The iron chelator deferasirox induces apoptosis by targeting oncogenic Pyk2/β-catenin signaling in human multiple myeloma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoates; beta Catenin; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Deferasirox; Dose-Response Relationship, Drug; Focal Adhesion Kinase 2; Humans; Iron; Iron Chelating Agents; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Phosphorylation; Reactive Oxygen Species; Time Factors; Triazoles; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
European drug agency launches website giving open access to trial data.
Topics: Access to Information; Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Europe; Gout; Gout Suppressants; Humans; Internet; Multiple Myeloma; Oligopeptides; Thioglycolates; Triazoles | 2016 |
XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bortezomib; Cell Line, Tumor; Cell Nucleus; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Exportin 1 Protein; Female; Gene Expression Regulation, Neoplastic; Humans; Hydrazines; Karyopherins; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Oligopeptides; Proteasome Endopeptidase Complex; Protein Stability; Proteolysis; Receptors, Cytoplasmic and Nuclear; RNA Interference; Time Factors; Transcription, Genetic; Transfection; Triazoles; Xenograft Model Antitumor Assays | 2016 |
Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Topics: Animals; Apoptosis; Azepines; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Multiple Myeloma; Nuclear Proteins; Proto-Oncogene Proteins c-myc; Reproducibility of Results; Signal Transduction; Transcription Factors; Transcription, Genetic; Triazoles; Xenograft Model Antitumor Assays | 2017 |
[Multiple myeloma complicated with disseminated zygomycosis after bortezomib therapy].
Topics: Acidosis; Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Echinocandins; Fatal Outcome; Humans; Lipopeptides; Male; Micafungin; Multiple Myeloma; Pyrazines; Pyrimidines; Triazoles; Tumor Lysis Syndrome; Voriconazole; Zygomycosis | 2010 |
BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Topics: Animals; Antineoplastic Agents; Azepines; Benzodiazepines; Cell Line, Tumor; Disease Models, Animal; Drug Discovery; Humans; Mice; Multiple Myeloma; Nuclear Proteins; Protein Structure, Tertiary; Proto-Oncogene Proteins c-myc; Transcriptional Activation; Triazoles | 2011 |
[Early onset of paralytic ileus caused by simultaneous administration of bortezomib and azole antifungals in multiple myeloma patients].
Topics: Aged; Antifungal Agents; Antineoplastic Agents; Boronic Acids; Bortezomib; Drug Interactions; Drug Therapy, Combination; Humans; Intestinal Pseudo-Obstruction; Itraconazole; Middle Aged; Multiple Myeloma; Mycoses; Pyrazines; Pyrimidines; Triazoles; Voriconazole | 2012 |
Successful control of disseminated Scedosporium prolificans infection with a combination of voriconazole and terbinafine.
Topics: Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Drug Synergism; Drug Therapy, Combination; Female; Follow-Up Studies; Fungemia; Humans; Immunocompromised Host; Microbial Sensitivity Tests; Middle Aged; Multiple Myeloma; Mycetoma; Naphthalenes; Opportunistic Infections; Pyrimidines; Risk Assessment; Scedosporium; Terbinafine; Treatment Outcome; Triazoles; Voriconazole | 2003 |
Successful treatment of disseminated aspergillosis with the combination of voriconazole, caspofungin, granulocyte transfusions, and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell
Topics: Antifungal Agents; Aspergillosis; Caspofungin; Drug Therapy, Combination; Echinocandins; Granulocytes; Humans; Leukocyte Transfusion; Lipopeptides; Magnetic Resonance Imaging; Male; Melphalan; Middle Aged; Multiple Myeloma; Necrosis; Peptides, Cyclic; Pyrimidines; Radiography; Stem Cell Transplantation; Transplantation, Autologous; Transplantation, Homologous; Triazoles; Voriconazole | 2005 |
Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections.
Topics: Adult; Antifungal Agents; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multiple Myeloma; Mycoses; Prospective Studies; Salvage Therapy; Transplantation, Homologous; Triazoles | 2007 |
[Rare pulmonary mycoses in patients with hematologic diseases].
Topics: Acremonium; Adolescent; Adult; Amphotericin B; Antifungal Agents; Antineoplastic Agents; Bone Marrow Transplantation; Female; Hematologic Neoplasms; Humans; Imidazoles; Leukemia, Myeloid, Acute; Lung; Lung Diseases, Fungal; Male; Middle Aged; Multiple Myeloma; Neutropenia; Penicillium; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pseudallescheria; Pyrimidines; Risk Factors; Triazoles; Voriconazole | 1998 |